<PAGE>   1


                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q/A

(Mark One)

  X      Quarterly report pursuant to Section 13 or 15(d) of the Securities
-----
         Exchange Act of 1934. For the quarterly period ended June 30, 1997.

         Transition report pursuant to Section 13 or 15(d) of the Securities 
-----
         Exchange Act of 1934.  For the transition period from     to     .
                                                              -----  ----- 

                         Commission File Number: 0-19749

                              CHEMTRAK INCORPORATED

    Delaware                                                 77-0295388
-------------------------------                          -----------------------
(State or other jurisdiction of                           (I.R.S Employer)
incorporation or organization)                           Identification No.)

                    929 E. Arques Avenue, Sunnyvale, CA 94086
                    -----------------------------------------
                    (Address of principal executive offices)

       Registrant's telephone number, including area code: (408) 773-8156

           Securities registered pursuant to Section 12(g) of the Act:

                          Common Stock $.001 par value
                          ----------------------------
                                (Title of Class)

        Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                               Yes  X  No 
                                  -----  -----

        Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.

Class: Common Stock $.001 par value   Outstanding at August 7, 1997: 12,994,006
       ----------------------------                                  -----------


<PAGE>   2


                              CHEMTRAK INCORPORATED
                                      INDEX



<TABLE>
<CAPTION>
PART I.        FINANCIAL INFORMATION                                                         PAGE
                                                                                             ----
                                                                                              NO.
                                                                                              ---

<S>                                                                                         <C>  
               Item 1:  Financial Statements

               Condensed Balance Sheets as of June 30, 1997 and December 31, 1996              3

               Condensed Statements of Operations for the three and six months ended
               June 30, 1997 and 1996                                                          4

               Condensed Statements of Cash Flows for the six months ended
               June 30, 1997 and 1996                                                          5

               Notes to Condensed Financial Statements                                       6-7

SIGNATURES                                                                                    13
</TABLE>


EXHIBITS



                                       2
<PAGE>   3



                             CHEMTRAK INCORPORATED
                            CONDENSED BALANCE SHEETS



                                     ASSETS


<TABLE>
<CAPTION>
                                                                                       June 30, 1997      December 30, 1996
                                                                                        ------------        ------------
                                                                                         (unaudited)           (Note)
<S>                                                                                     <C>                 <C>         
Current assets:
   Cash and cash equivalents                                                            $  1,875,000        $  4,125,000
   Short-term investments                                                                         --             567,000
   Accounts receivable, net                                                                  520,000             485,000
   Inventories                                                                             1,523,000             540,000
   Prepaid expenses and other current assets                                                 131,000             320,000
                                                                                        ------------        ------------
      Total current assets                                                                 4,049,000           6,037,000
   Property and equipment, net                                                             2,286,000           2,738,000
   Other assets                                                                               66,000              66,000
                                                                                        ------------        ------------
Total assets                                                                            $  6,401,000        $  8,841,000
                                                                                        ============        ============


                                             LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
   Accounts payable                                                                     $    248,000        $    289,000
   Accrued payroll and benefits                                                              165,000             199,000
   Other accrued liabilities                                                                 791,000             788,000
   Accrued royalties                                                                         149,000             105,000
                                                                                        ------------        ------------
      Total current liabilities                                                            1,353,000           1,381,000

Deferred Revenue                                                                             350,000                  --    

Accrued rent                                                                                 315,000             295,000

Convertible debentures                                                                       506,000           2,135,000

Stockholders' equity:
   Common stock                                                                               13,000              12,000
   Additional paid-in capital                                                             43,160,000          41,375,000
   Deferred compensation                                                                     (39,000)            (49,000)
   Accumulated deficit                                                                   (39,257,000)        (36,308,000)
                                                                                        ------------        ------------
      Total stockholders' equity                                                           3,877,000           5,030,000
                                                                                        ------------        ------------

Total liabilities and stockholders' equity                                              $  6,401,000        $  8,841,000
                                                                                        ============        ============
</TABLE>

        Note:   The balance sheet at December 31, 1996 has been derived from the
audited financial statements at that date, but does not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements.



                             See accompanying notes.


                                       3


<PAGE>   4



                              CHEMTRAK INCORPORATED
                       CONDENSED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)


<TABLE>
<CAPTION>
                                                         Three months ended                      Six months ended
                                                               June 30,                               June 30,
                                                   --------------------------------        --------------------------------
                                                       1997               1996                1997                 1996
                                                   ------------        ------------        ------------        ------------
<S>                                                <C>                 <C>                 <C>                 <C>         
Net revenues:
    Product sales                                  $    870,000        $    581,000        $  1,478,000        $  1,437,000
    Funded research and other revenues                       --              25,000             833,000             175,000
                                                   ------------        ------------        ------------        ------------
        Total net revenues                              870,000             606,000           2,311,000           1,612,000

Cost and expenses:
    Cost of product sales                               517,000             824,000           1,221,000           1,555,000
    Research and development                            579,000             729,000           1,032,000           1,473,000
    Marketing, general and administrative             1,530,000           1,179,000           3,153,000           2,273,000
                                                   ------------        ------------        ------------        ------------

        Total costs and expenses                      2,626,000           2,732,000           5,406,000           5,301,000
                                                   ------------        ------------        ------------        ------------

Operating loss                                       (1,756,000)         (2,126,000)         (3,095,000)         (3,689,000)

Interest income and (expense), net                      102,000            (663,000)            146,000            (596,000)
                                                   ------------        ------------        ------------        ------------

Net loss                                           $ (1,654,000)       $ (2,789,000)       $ (2,949,000)       $ (4,285,000)
                                                   ============        ============        ============        ============
Net loss per share                                 $      (0.13)       $      (0.29)       $      (0.24)       $      (0.44)
                                                   ============        ============        ============        ============

Shares used in calculating per share amounts         12,855,000           9,773,000          12,470,000           9,743,000
                                                   ============        ============        ============        ============
</TABLE>


                                       4


<PAGE>   5


                              CHEMTRAK INCORPORATED
                       CONDENSED STATEMENTS OF CASH FLOWS
                INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
                                   (UNAUDITED)


<TABLE>
<CAPTION>
                                                                                 Six months ended
                                                                                     June 30,
                                                                       -------------------------------------
                                                                              1997                1996
                                                                       -----------------   -----------------
<S>                                                                       <C>                   <C>         
Operating activities:
   Net loss                                                               $  (2,949,000)        $(4,285,000)
   Adjustment to reconcile net loss to net cash and
     cash equivalents used in operating activities:
       Depreciation and amortization                                            403,000             430,000
       Interest expense and financing charges
       on convertible debentures                                                105,000             619,000
       Accrued rent                                                              20,000              27,000
       Stock option compensation and other                                           --               2,000
       Loss on disposal of assets                                               170,000                  --
   Changes in operating assets and liabilities:
       Accounts receivable                                                      (35,000)           (364,000)
       Inventories                                                             (983,000)           (266,000)
       Prepaid expenses and other current assets                                189,000             167,000
       Accounts payable                                                         (41,000)           (183,000)
       Accrued payroll and benefits                                             (34,000)             36,000
       Deferred Revenue                                                         350,000                  --
       Accrued royalties and other accrued liabilities                           47,000             349,000

                                                                       -----------------   -----------------
            Net cash and cash equivalents 
              used in operating activities                                   (2,758,000)         (3,468,000)
                                                                       -----------------   -----------------


Investing activities:
   Proceeds from available-for-sale securities                                  567,000             514,000
   Acquisition of property and equipment, net                                  (121,000)           (190,000)
                                                                       -----------------   -----------------

            Net cash and cash equivalents provided
             by investing activities                                            446,000             324,000
                                                                       -----------------   -----------------

Financing activities:
   Net proceeds from issuance of convertible debentures                              --           4,700,000
   Issuance of common stock                                                      62,000             182,000
                                                                       -----------------   -----------------

            Net cash and cash equivalents provided
             by financing activities                                             62,000           4,882,000
                                                                       -----------------   -----------------

Net increase (decrease) in cash and cash equivalents                         (2,250,000)          1,738,000
Cash and cash equivalents at beginning of period                              4,125,000           4,251,000
                                                                       -----------------   -----------------
Cash and cash equivalents at end of period                                $   1,875,000         $ 5,989,000
                                                                       =================   =================


Supplemental disclosure of non-cash financing activities:
Conversion of convertible debentures and accrued
   interest to common stock                                               $   1,629,000           $      --
                                                                       =================   =================
</TABLE>

                             See accompanying notes.


                                       5


<PAGE>   6


                              CHEMTRAK INCORPORATED

                     NOTES TO CONDENSED FINANCIAL STATEMENTS

                                  June 30, 1997

                                   (unaudited)

Note 1.  Basis of Presentation

        The accompanying unaudited financial statements include all adjustments
consisting of normal recurring adjustments which the Company's management
believes to be necessary to fairly present the Company's financial position as
of June 30, 1997, and the results of operations for the three and six month
periods ended June 30, 1997.


        The operating results of the interim periods presented are not
necessarily indicative of the results for the full year. The accompanying
financial statements should be read in conjunction with the financial statements
for the year ended December 31, 1996, included in the ChemTrak Incorporated
Annual Report on Form 10-K for the fiscal year ended December 31, 1996 (the
"Form 10-K"), and the 1996 Annual Report to Stockholders (the "Annual Report").
The information set forth in the accompanying balance sheet as of December 31,
1996, has been derived from the audited balance sheet included in the
above-referenced Form 10-K and Annual Report.

Note 2.  Net Loss Per Share

        Net loss per share is computed using the weighted average number of
shares outstanding. Common equivalent shares from stock options are excluded in
the computation as their effect is antidilutive.

        In February 1997, the Financial Accounting Standards Board issued
Statement No. 128, Earnings per Share, which ChemTrak is required to adopt on
December 31, 1997. At that time, the Company will be required to change the
method currently used to compute loss per share and to restate all prior
periods. Under the new requirements for calculating primary loss per share, the
dilutive effect of stock options will be excluded. The primary loss per share
for the three and six month period ended June 30, 1997 and June 30, 1996 would
not change as reported. The impact of Statement 128 is expected not to have a
material effect on fully diluted loss per share. 


                                       6


<PAGE>   7


                              CHEMTRAK INCORPORATED

               NOTES TO CONDENSED FINANCIAL STATEMENTS (continued)

                                  June 30, 1997

                                   (unaudited)



Note 3.  Inventories

        Inventories are stated at the lower of standard cost (which approximates
actual costs on a first-in, first-out basis) or market. Inventories consisted of
the following:


<TABLE>
<CAPTION>
                    June 30, 1997    December 31,1996
                      ----------       ----------
<S>                   <C>              <C>       
Raw materials.......  $  728,000       $  289,000
Work in process.....     182,000           63,000
Finished goods......     613,000          188,000
                      ----------       ----------
  Total.............  $1,523,000       $  540,000
                      ==========       ==========
</TABLE>


Note 4.  Convertible Debentures

        In May 1996, the Company issued $5,000,000 of convertible debentures
resulting in net proceeds to the company of $4,700,000 after deducting selling
commissions. The debentures, which are due in May 1998, are convertible into
common stock at the lower of 110% of the average closing prices during the
ten-day trading period ending with the initial debenture funding date, or 82.5
percent of the similarly-defined average ten-day market price ending with the
conversion date. The Company has the option to convert the amount of periodic
interest due on the convertible debentures, computed at the rate of 7.5% per
annum, into common stock of the Company in lieu of cash payments. Through June
30, 1997, all interest obligations on the debentures have been settled by the
issuance of common stock.

        The accompanying financial statements reflect deemed non-cash interest
expense of $875,000 ($656,250 and $218,750 in the quarters ended June 30, 1996
and September 30, 1996, respectively).

        As of June 30, 1997, aggregate principal amount of $4,605,000 had been
converted into 3,013,000 shares of common stock and approximately 84,436 shares
were issued to settle interest obligations.


                                       7


<PAGE>   8


                              CHEMTRAK INCORPORATED

                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.


Date:   August 14, 1997                   CHEMTRAK INCORPORATED


                                    /s/ Donald V. Fluken
                                    -----------------------------------------
                                    Donald V. Fluken
                                    Chief Financial Officer
                                   (Principal Financial and Accounting Officer)